期刊
INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
卷 41, 期 2, 页码 809-817出版社
SPANDIDOS PUBL LTD
DOI: 10.3892/ijmm.2017.3260
关键词
cisplatin; ovarian cancer; calcium; endoplasmic reticulum; peptide
资金
- National Nature and Science Foundation of China (NSFC) [81372793, 81472419, 81202552]
- Department of Education of Jilin Province Project [2016237]
Ovarian cancer is the most common gynecological malignancy. At present, cisplatin is used to treat ovarian cancer; however, the development of cisplatin resistance during therapy is a common obstacle to achieving favorable outcomes. Recently, the B-cell lymphoma 2 (Bcl-2) BH4 domain has been reported to mediate the prosurvival activity of Bcl-2 in cancer; however, the involvement of the BH4 domain of Bcl-2 in the cisplatin resistance of ovarian carcinoma cells is not entirely clear. In this study, we observed the cytoplasmic and mitochondrial levels of Ca2+ by confocal laser microscopy. We also detected cell apoptosis using western blot analysis and flow cytometry. The present study demonstrated that TAT-fused inositol 1,4,5-trisphosphate receptor-derived peptide (TAT-IDPS), which targets the BH4 domain of Bcl-2, increased cisplatin-induced Ca2+ flux from the endoplasmic reticulum (ER) into the cytosol and mitochondria. In addition, TAT-IDPS increased cisplatin-induced expression of mitochondrial apoptosis-associated proteins and ER stress-associated proteins. These results indicated that TAT-IDPS may enhance the cytotoxicity of cisplatin toward ovarian carcinoma cells by increasing ER Ca2+ release.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据